A phase 2, multicentre, single-arm, open-label study to evaluate the safety and efficacy of single-agent lenalidomide (Revlimid®) in subjects with relapsed or refractory peripheral T-cell non-Hodgkin lymphoma: The EXPECT trial-Reference-Cited by-同舟云学术

A phase 2, multicentre, single-arm, open-label study to evaluate the safety and efficacy of single-agent lenalidomide (Revlimid®) in subjects with relapsed or refractory peripheral T-cell non-Hodgkin lymphoma: The EXPECT trial

Published:2013-09 Issue:13 Volume:49 Page:2869-2876
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Morschhauser Franck,Fitoussi Olivier,Haioun Corinne,Thieblemont Catherine,Quach Hang,Delarue Richard,Glaisner Sylvie,Gabarre Jean,Bosly André,Lister John,Li Ju,Coiffier Bertrand

Funder

Celgene Corporation

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference30 articles.

1. Report of an international workshop to standardize response criteria for non-Hodgkin’s lymphomas. NCI Sponsored International Working Group;Cheson;J Clin Oncol,1999

2. Peripheral T-cell lymphomas have a worse prognosis than B-cell lymphomas: a prospective study of 361 immunophenotyped patients treated with the LNH-84 regimen. The GELA (Groupe d’Etude des Lymphomes Agressives);Coiffier;Ann Oncol,1990

3. Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy;Coiffier;J Clin Oncol,2012

4. Phase II trial of zanolimumab (HuMax-CD4) in relapsed or refractory non-cutaneous peripheral T cell lymphoma;d’Amore;Br J Haematol,2010

5. Pentostatin in T-non-Hodgkin’s lymphomas: efficacy and effect on CD26+ T lymphocytes;Dang;Oncol Rep,2003

Cited by 111 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeted agents plus CHOP compared with CHOP as the first-line treatment for newly diagnosed patients with peripheral T-cell lymphoma (GUIDANCE-03): an open-label, multicentre phase 2 clinical trial;The Lancet Regional Health - Western Pacific;2024-09

2. Treatment strategies and outcome in relapsed peripheral T-cell lymphoma: results from the Netherlands Cancer Registry;Blood Advances;2024-07-10

3. Novel clinical risk stratification and treatment strategies in relapsed/refractory peripheral T-cell lymphoma;Journal of Hematology & Oncology;2024-06-01

4. How I treat peripheral T-cell lymphomas;Russian journal of hematology and transfusiology;2024-03-19

5. Aggressive T‐cell lymphomas: 2024: Updates on diagnosis, risk stratification, and management;American Journal of Hematology;2024-02-02